John Kleckner, an insider at Enovis Corp (ENOV), purchased 12,302 shares of the company's stock at a price of $30.32 per share, amounting to a total transaction value of $373,000. This transaction occurred on November 24, 2025. Following this acquisition, Kleckner now holds 12,302 shares in Enovis Corp.
Enovis Corp operates as a medical technology growth company based in Wilmington, Delaware, employing 7,367 full-time staff. The company focuses on developing clinically differentiated solutions, manufacturing and distributing high-quality medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive.
The Prevention & Recovery segment offers orthopedic solutions, including devices and software, while the Reconstructive segment provides a comprehensive suite of surgical implant solutions. Enovis Corp went public on May 8, 2008, and currently has a market capitalization of $1.7 billion, with a trailing twelve-month EPS of -24.20.
Insider transactions, such as this purchase, are reported to the SEC and provide transparency regarding how executives view their company's stock. While insider buying can indicate confidence in a company's future, it should be considered alongside other fundamental and technical factors. Investors are encouraged to analyze patterns of insider activity over time and across multiple insiders to gain a more comprehensive understanding of market sentiment.
Enovis Corp is set to report its upcoming earnings on May 6, 2026, with an estimated EPS of $0.78 and revenue of $593.3 million, followed by another report on August 5, 2026, with an estimated EPS of $0.87 and revenue of $604.3 million.